IC

Incyte Corporation

Every trial this sponsor leads in the registry, and everything it has published.

288All trials
Recruiting27
Recruited29
Not yet recruiting2
Completed150
Stopped80

58 active · 20% of this sponsor’s registry footprint

Oncology30 trials
Dermatology11 trials
Immunology & Inflammation7 trials
Gastroenterology & Hepatology1 trial
Haematology1 trial
Renal & Urology1 trial
Respiratory1 trial

Not shown above: 3 Phase 1 healthy-volunteer trials and 3 trials whose condition matched no therapy area.

Trials by phase

Phase 1126
Phase 2100
Phase 361
Phase 41

Pipeline by phase · 22 drugs in active development

Phase 3 · 9 drugs

povorcitinib9 trials · 3 recruitingest. Oct 2026
Ruxolitinib7 trials · 3 recruitingest. Oct 2026
Axatilimab (INCA034176)6 trials · 2 recruitingest. Jan 2027
tafasitamab6 trials · 1 recruitingest. Aug 2027
INCB1236675 trials · 4 recruitingest. Jan 2027
INCA0339894 trials · 3 recruitingest. Oct 2026
INCB1617343 trials · 2 recruitingest. Oct 2026
INCA338902 trials · 2 recruitingest. Dec 2028

Phase 2 · 5 drugs

INCB0992802 trialsest. Sept 2026
Zilurgisertib (INCB000928)2 trials · 1 recruitingest. Jul 2027
INCA0005851 trial · 1 recruitingest. Sept 2027
Parsaclisib1 trialest. Nov 2026
Retifanlimab1 trial

Phase 1 · 8 drugs

INCA0357841 trial · 1 recruitingest. Mar 2028
INCA0368731 trial · 1 recruitingest. Aug 2028
INCA0369781 trial · 1 recruitingest. May 2030
INCB01236671 trialest. Jul 2027
INCB0576431 trialest. Apr 2027
INCB1600581 trialest. Oct 2028
INCB1867481 trialest. Mar 2027
Ponatinib1 trial · 1 recruitingest. Feb 2028

Active trials only, code names and brands merged. 150 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 3 of 10 curated

Breast cancer (Oncology)2 trials · 2 drugs0.1% of landscape
Non-small cell lung cancer (Oncology)2 trials · 1 recruiting · 2 drugs0.1% of landscape
Atopic dermatitis (Dermatology)1 trial · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon